Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.
Certara, Inc. (NASDAQ: CERT) delivers biosimulation solutions and model-informed drug development services that accelerate pharmaceutical innovation. This page provides comprehensive coverage of Certara's latest news, including regulatory milestones, strategic partnerships, and advancements in simulation technology.
Investors and industry professionals will find timely updates on earnings reports, product launches, and scientific developments shaping the drug development landscape. Our curated collection features press releases on regulatory submissions, technology platform enhancements, and collaborations with biopharma leaders.
Key focus areas include Certara's biosimulation software updates, regulatory science achievements, and innovations in quantitative pharmacology. Bookmark this page to stay informed about developments impacting clinical trial optimization and global drug approval processes.
Certara has announced the acquisition of Vyasa Analytics, enhancing its software capabilities with advanced deep-learning technology aimed at the life sciences sector. This acquisition will integrate Vyasa's AI-driven solutions, including the LAYAR data platform, into Certara's biosimulation software, broadening its product offerings and improving decision-making in drug development. Certara serves over 2,000 clients globally, leveraging proprietary software to accelerate drug discovery and development.
Certara, Inc. (Nasdaq: CERT) has completed a $449 million stock purchase from funds controlled by EQT Private Equity, marking a significant investment by Arsenal Capital Partners. As part of this deal, David Spaight, an Operating Partner at Arsenal, has been appointed to Certara’s Board of Directors. Arsenal has committed to a two-year lock-up period, reflecting its long-term commitment as a shareholder. Spaight's extensive experience in the biopharmaceutical sector is expected to enhance Certara’s strategic direction and growth prospects.
Certara, Inc. (Nasdaq: CERT) reported significant growth for Q3 2022, achieving $84.7 million in revenue, a 15% increase year-over-year. This growth was complemented by a net income of $3.9 million, a notable turnaround from a net loss of $1.8 million in the same quarter last year. Adjusted EBITDA rose 25% to $32.7 million. The company reiterated its full-year revenue guidance of $325 million to $335 million. Additionally, Arsenal Investment Partners is set to acquire 30 million shares at $15 per share, strengthening shareholder support.
Certara (Nasdaq: CERT) has announced a significant investment from Arsenal Capital Partners, acquiring approximately 30 million shares at $15 each, totaling around $449 million. Once completed, Arsenal's stake will rise to about 22% of diluted shares outstanding. This investment is subject to HSR regulatory approval and includes a two-year lock-up on share sales. Arsenal is a long-time investor in Certara, which specializes in biosimulation for drug development.
Certara, Inc. (Nasdaq: CERT) has announced its participation in two upcoming investor conferences. The first is the Jeffries London Healthcare Conference on November 15 at 4:25 PM GMT, followed by the Stephens Annual Investment Conference on November 17 at 9:00 AM CT. Live webcasts will be available on Certara's investor relations website and can be replayed for 90 days. Certara specializes in biosimulation software and services that enhance drug discovery and development for over 2,000 clients worldwide.
Certara has announced the renewal of its software licenses with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the ninth consecutive year.
Certara's Simcyp™ Simulator, Phoenix™, and Pinnacle 21™ Enterprise software will continue to support PMDA in drug development and regulatory submissions.
The PMDA has utilized Certara’s software since 2014, significantly enhancing its data validation processes, including new compliance rules introduced in 2021.
Certara collaborates with over 140 biopharmaceutical companies in Japan, including the top 20 by R&D spending.
Certara, a leader in biosimulation, will release its Q3 2022 financial results on November 7, 2022, after market close. A conference call with management will follow at 5:00 p.m. ET to discuss the results. Interested investors must register online, ideally a day in advance. The event will be accessible via a live and archived webcast on the Certara website. The company aids over 2,000 clients globally in drug discovery and development through its innovative software and services.
Certara, Inc. (Nasdaq: CERT), a leader in biosimulation, will participate in two upcoming investor conferences. The first is the Morgan Stanley 20th Annual Global Healthcare Conference on September 13 at 11:45 a.m. ET. The second is the Baird Global Healthcare Conference on September 14 at 12:15 p.m. ET. Live webcasts will be available on Certara’s investor relations website and can be replayed for 90 days. Certara uses advanced biosimulation software to enhance drug discovery and development for over 2,000 clients in 62 countries.
Certara, Inc. (Nasdaq: CERT) announced an underwritten secondary offering of 7,000,000 shares of common stock by certain stockholders, including EQT Avatar Parent L.P. The offering allows for a 30-day option for the underwriter to purchase an additional 1,050,000 shares. No shares are being sold by Certara, and the proceeds will go entirely to the Selling Stockholders. The last reported stock price was $20.19, with the closing expected around August 16, 2022. Morgan Stanley is the underwriter for this offering.
Certara reported a strong second quarter of fiscal year 2022, achieving $82.8 million in revenue, an 18% increase compared to the prior year. Revenue excluding Pinnacle 21 was $75.8 million, up 8%. Net loss decreased to $0.6 million from $2.9 million, marking a significant improvement. Adjusted EBITDA rose to $28.0 million, reflecting 9% growth. While full-year guidance has been adjusted to $325-$335 million due to currency fluctuations and slow regulatory market recovery, Certara remains optimistic about its biosimulation and Pinnacle 21 services.
